Stocks and Investing
Stocks and Investing
Thu, November 2, 2023
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
Gena Wang Maintained (BMRN) at Buy with Decreased Target to $111 on, Nov 2nd, 2023
Gena Wang of Barclays, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Decreased Target from $125 to $111 on, Nov 2nd, 2023.
Gena has made no other calls on BMRN in the last 4 months.
There are 12 other peers that have a rating on BMRN. Out of the 12 peers that are also analyzing BMRN, 6 agree with Gena's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- William Pickering of "Bernstein" Upgraded from Sell to Hold and Held Target at $82 on, Monday, October 23rd, 2023
- Laura Chico of "Raymond James" Initiated at Hold on, Thursday, September 28th, 2023
- Luca Issi of "RBC Capital" Reiterated at Hold and Held Target at $100 on, Wednesday, September 13th, 2023
- Andreas Argyrides of "Wedbush" Maintained at Hold with Decreased Target to $70 on, Tuesday, August 1st, 2023
- George Farmer of "Scotiabank" Initiated at Hold and Held Target at $95 on, Thursday, July 27th, 2023
- Whitney Ijem of "Canaccord Genuity" Maintained at Hold with Decreased Target to $104 on, Monday, July 3rd, 2023
These are the ratings of the 6 analyists that currently disagree with Gena
- Robyn Karnauskas of "Truist Securities" Reiterated at Strong Buy and Held Target at $140 on, Monday, September 25th, 2023
- Martin Auster of "UBS" Initiated at Strong Buy and Held Target at $120 on, Monday, September 18th, 2023
- Debjit Chattopadhyay of "Guggenheim" Reiterated at Strong Buy and Held Target at $110 on, Wednesday, September 13th, 2023
- Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $108 on, Tuesday, August 1st, 2023
- Geoff Meacham of "B of A Securities" Maintained at Strong Buy with Decreased Target to $185 on, Friday, July 21st, 2023
- Kostas Biliouris of "BMO Capital" Upgraded from Hold to Buy and Held Target at $102 on, Wednesday, July 5th, 2023
Contributing Sources